Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Wild-type Reovirus · 1 trial · 2 indications
The safety of the bortezomib, dexamethasone, and wild-type reovirus combination will be assessed by the evaluation of the type, frequency, and severity of adverse events.
| Arm | Type | Description |
|---|---|---|
| Treatment (dexamethasone, bortezomib, wild-type reovirus) | EXPERIMENTAL | Patients receive dexamethasone PO, IV, or IM and bortezomib SC (preferably) or IV over 3-5 seconds on days 1, 8, and 15. Patients also receive wild-type reovirus IV over 60 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| Bortezomib | DRUG | Given SC or IV |
| Dexamethasone | DRUG | Given PO, IV, or IM |
| Laboratory Biomarker Analysis | OTHER | Correlative studies |
| Pharmacological Study | OTHER | Correlative studies |
| Wild-type Reovirus | BIOLOGICAL | Given IV |
Inclusion Criteria: * Have relapsed or refractory MM after at least one line of therapy * Have a confirmed diagnosis of MM with measurable disease, as defined by the presence of monoclonal immunoglobulin protein in serum electrophoreses of at least 0.5 g/dL for immunoglobulin G (IgG) or 0.25 g/dL f...
Wild-type Reovirus is an investigational oncolytic virus being studied for the treatment of recurrent plasma cell myeloma, also known as relapsed or refractory multiple myeloma. It is being evaluated in combination with bortezomib and dexamethasone in patients with this condition.
Wild-type Reovirus is being developed by Oncolytics Biotech Inc., a biopharmaceutical company traded under the ticker symbol ONCY. The company is conducting clinical research to evaluate the drug's safety and efficacy in oncology indications.
Wild-type Reovirus is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed to assess its use in patients with recurrent or refractory plasma cell myeloma.
Wild-type Reovirus has been studied in one completed Phase 1 clinical trial, identified as NCT02514382. This trial evaluated the drug in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma, enrolling 14 participants in the United States.
Wild-type Reovirus is classified as a monoclonal antibody modality in the context of this development program. However, it is an oncolytic virus being investigated for its potential to treat cancer, specifically recurrent plasma cell myeloma.